207 related articles for article (PubMed ID: 12792492)
1. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
Gao L; Xue SA; Hasserjian R; Cotter F; Kaeda J; Goldman JM; Dazzi F; Stauss HJ
Transplantation; 2003 May; 75(9):1429-36. PubMed ID: 12792492
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
3. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
4. WT1-targeted immunotherapy of leukaemia.
Xue S; Gao L; Gillmore R; Bendle G; Holler A; Downs AM; Tsallios A; Ramirez F; Ghani Y; Hart D; Alcock S; Tranter A; Stauss HJ; Morris E
Blood Cells Mol Dis; 2004; 33(3):288-90. PubMed ID: 15528146
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
6. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG
Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984
[TBL] [Abstract][Full Text] [Related]
7. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.
Doubrovina ES; Doubrovin MM; Lee S; Shieh JH; Heller G; Pamer E; O'Reilly RJ
Clin Cancer Res; 2004 Nov; 10(21):7207-19. PubMed ID: 15534094
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
[TBL] [Abstract][Full Text] [Related]
9. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
10. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro.
Maurer U; Brieger J; Weidmann E; Mitrou PS; Hoelzer D; Bergmann L
Exp Hematol; 1997 Aug; 25(9):945-50. PubMed ID: 9257807
[TBL] [Abstract][Full Text] [Related]
11. Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by cotransplantation of a second unrelated cord blood unit.
Nauta AJ; Kruisselbrink AB; Lurvink E; Mulder A; Claas FH; Noort WA; Willemze R; Fibbe WE
Exp Hematol; 2005 Oct; 33(10):1249-56. PubMed ID: 16219548
[TBL] [Abstract][Full Text] [Related]
12. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess.
Madlambayan GJ; Rogers I; Purpura KA; Ito C; Yu M; Kirouac D; Casper RF; Zandstra PW
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1020-30. PubMed ID: 17084368
[TBL] [Abstract][Full Text] [Related]
14. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
15. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
16. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients.
Danet-Desnoyers GA; Luongo JL; Bonnet DA; Domchek SM; Vonderheide RH
Exp Hematol; 2005 Nov; 33(11):1275-80. PubMed ID: 16263411
[TBL] [Abstract][Full Text] [Related]
17. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor promotes human T-cell development in nonobese diabetic/severe combined immunodeficient mice.
Samira S; Ferrand C; Peled A; Nagler A; Tovbin Y; Ben-Hur H; Taylor N; Globerson A; Lapidot T
Stem Cells; 2004; 22(6):1085-100. PubMed ID: 15536198
[TBL] [Abstract][Full Text] [Related]
19. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
[TBL] [Abstract][Full Text] [Related]
20. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
